Our group provided an early exemplary case where a CML patient harboring the T315I and E255V BCR-ABL1 mutations achieved successful DMR using dasatinib combined with IFN-α (82). This evidence concerns the gene IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive.